The Experts below are selected from a list of 432 Experts worldwide ranked by ideXlab platform

Richard F Clark - One of the best experts on this subject based on the ideXlab platform.

N. Ferrara - One of the best experts on this subject based on the ideXlab platform.

  • Hypermagnesemia predicts mortality in elderly with congestive heart disease relationship with laxative and antacid use
    Rejuvenation Research, 2008
    Co-Authors: G. Corbi, D. Acanfora, G. Longobardi, F. Cacciatore, G. Furgi, G. Rengo, D. Leosco, Gian Luca Iannuzzi, Amelia Filippelli, N. Ferrara
    Abstract:

    ABSTRACT The aim of this study was to evaluate the role of magnesium levels on 3-year survival in the elderly with congestive heart failure (CHF) admitted to the Rehabilitative Cardiology Unit of S. Maugeri Foundation Scientific Institute of Telese/Campoli. All elderly patients ≥ 65 years old with a diagnosis of CHF underwent clinical and instrumental examination, and their demographics, co-morbidity, and in-hospital and 3-year mortality rates were recorded. Hypomagnesemia was found in 4.8%, normomagnesemia in 67.5%, and Hypermagnesemia in 27.8% of subjects. The hypomagnesemic group was excluded for numerical exiguity; the analysis was performed on a total of 199 elderly patients. Hypermagnesemia was found in 29.1% and normomagnesemia in 70.9%. At the univariate analysis no differences were found in Hypermagnesemia in respect to normomagnesemia group, except for slightly higher levels of creatininemia (1.35 ± 0.61 vs. 1.13 ± 0.55 mg/dL, respectively; p < 0.02), greater disability (lost ADL, 2.69 ± 1.57 vs...

  • Hypermagnesemia predicts mortality in elderly with congestive heart disease: relationship with laxative and antacid use.
    'Mary Ann Liebert Inc', 2008
    Co-Authors: G. Corbi, D. Acanfora, L. G. Iannuzzi, G. Longobardi, F. Cacciatore, G. Furgi, Filippelli Amelia, G. Rengo, D. Leosco, N. Ferrara
    Abstract:

    The aim of this study was to evaluate the role of magnesium levels on 3-year survival in the elderly with congestive heart failure (CHF) admitted to the Rehabilitative Cardiology Unit of S. Maugeri Foundation Scientific Institute of Telese/Campoli. All elderly patients > or = 65 years old with a diagnosis of CHF underwent clinical and instrumental examination, and their demographics, co-morbidity, and in-hospital and 3-year mortality rates were recorded. Hypomagnesemia was found in 4.8\%, normomagnesemia in 67.5\%, and Hypermagnesemia in 27.8\% of subjects. The hypomagnesemic group was excluded for numerical exiguity; the analysis was performed on a total of 199 elderly patients. Hypermagnesemia was found in 29.1\% and normomagnesemia in 70.9\%. At the univariate analysis no differences were found in Hypermagnesemia in respect to normomagnesemia group, except for slightly higher levels of creatininemia (1.35 +/- 0.61 vs. 1.13 +/- 0.55 mg/dL, respectively; p < 0.02), greater disability (lost ADL, 2.69 +/- 1.57 vs. 2.15 +/- 1.56, respectively; p < 0.05), more mortality for CHF (32.6 vs. 48.3\%; p < 0.05), and higher antacid and laxative use (82.7 vs. 24.8\%, respectively; p < 0.0001). Patients with higher magnesium showed less probability to survive at a 3-year follow-up than did patients with lower levels (17.32 +/- 15.93 vs. 22.46 +/- 16.16 months; p < 0.05), and this finding remained significant in the multivariate analysis after adjusting for some confounders. Finally Hypermagnesemia should also be considered in the absence of pre-existing renal failure clinical evidence because of its negative prognostic value, especially in elderly patients with CHF. The shown relationship between Hypermagnesemia and laxative/antacid use should induce physicians to pay more attention to abuse of these drugs

Sean Patrick Nordt - One of the best experts on this subject based on the ideXlab platform.

Z S Agus - One of the best experts on this subject based on the ideXlab platform.

  • hypomagnesemia renal magnesium handling
    Seminars in Nephrology, 1998
    Co-Authors: E Kelepouris, Z S Agus
    Abstract:

    : Magnesium is an important constituent of the intracellular space that affects a number of intracellular and whole body functions. Magnesium balance depends on intake and renal excretion, which is regulated mainly in the thick ascending limb of the loop of Henle. The complex hormonal modulation that responds to changes in plasma concentration of other ions such as calcium and potassium is lacking for magnesium. As a result, negative magnesium balance results in a prompt decrease in plasma magnesium concentration, and Hypermagnesemia accompanies renal failure with magnesium accumulation. Hypomagnesemia may result from gastrointestinal losses or renal losses, the latter due to primary renal magnesium wasting or in association with sodium loss. Hypomagnesemia may arise together with and contribute to the persistence of hypokalemia and hypocalcemia. The major direct toxicity of hypomagnesemia is cardiovascular. When urgent correction of hypomagnesemia is required, as with myocardial ischemia, post cardiopulmonary bypass, and torsades de pointes, intravenous or intramuscular magnesium sulfate should be used. Oral magnesium preparations are available for chronic use.

David J Leehey - One of the best experts on this subject based on the ideXlab platform.

  • magnesium and dialysis the neglected cation
    American Journal of Kidney Diseases, 2015
    Co-Authors: Mohamad Alhosaini, David J Leehey
    Abstract:

    Disorders of magnesium homeostasis are very common in dialysis patients but have received scant attention. In this review, we address measurement of plasma magnesium, magnesium balance and the factors that affect magnesium flux during dialysis, the prevalence of hypo- and Hypermagnesemia in dialysis patients, and the potential clinical significance of hypo- and Hypermagnesemia in dialysis patients. Many factors can affect plasma magnesium concentration, including diet, nutritional status (including plasma albumin level), medications (such as proton pump inhibitors), and dialysis prescription. Further interventional studies to determine the effect of normalization of plasma magnesium concentration on clinical outcomes are needed. At the present time, we recommend that predialysis plasma magnesium be measured on a regular basis, with the dialysate magnesium concentration adjusted to maintain plasma magnesium concentration within the normal range.